653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564
2021
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI